{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:39:30Z","timestamp":1768282770581,"version":"3.49.0"},"reference-count":129,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Cases of autoimmune bullous dermatosis (AIBD) have been reported following COVID-19 vaccination. Objective: We aimed to provide an overview of clinical characteristics, treatments, and outcomes of AIBDs following COVID-19 vaccination. Methods: We conducted a systematic review and searched the Embase, Cochrane Library, and Medline databases from their inception to 27 March 2024. We included all studies reporting \u2265 1 patient who developed new-onset AIBD or experienced flare of AIBD following at least one dose of any COVID-19 vaccine. Results: We included 98 studies with 229 patients in the new-onset group and 216 in the flare group. Among the new-onset cases, bullous pemphigoid (BP) was the most frequently reported subtype. Notably, mRNA vaccines were commonly associated with the development of AIBD. Regarding the flare group, pemphigus was the most frequently reported subtype, with the mRNA vaccines being the predominant vaccine type. The onset of AIBD ranged from 1 to 123 days post-vaccination, with most patients displaying favorable outcomes and showing improvement or resolution from 1 week to 8 months after treatment initiation. Conclusions: Both new-onset AIBD and exacerbation of pre-existing AIBD may occur following COVID-19 vaccination. Healthcare practitioners should be alert, and post-vaccination monitoring may be essential.<\/jats:p>","DOI":"10.3390\/vaccines12050465","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T09:50:07Z","timestamp":1714470607000},"page":"465","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2218-6083","authenticated-orcid":false,"given":"Po-Chien","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou Main Branch, Taoyuan 33305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8136-0619","authenticated-orcid":false,"given":"I-Hsin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou Main Branch, Taoyuan 33305, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1118-0900","authenticated-orcid":false,"given":"Ching-Ya","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Heping Fuyou Branches, Taipei City Hospital Renai, Taipei 10629, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5699-0283","authenticated-orcid":false,"given":"Ching-Chi","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chang Gung Memorial Hospital, Linkou Main Branch, Taoyuan 33305, Taiwan"},{"name":"School of Medicine, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ds.ds_17_22","article-title":"Aiming at a bright future","volume":"40","author":"Chi","year":"2022","journal-title":"Dermatol. Sin."},{"key":"ref_3","unstructured":"World Health Organization (WHO) (2023, April 25). WHO Coronavirus (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaad.2021.09.002","article-title":"Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study","volume":"86","author":"McMahon","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.annder.2021.07.008","article-title":"Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine","volume":"149","author":"Agharbi","year":"2022","journal-title":"Ann. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e15396","DOI":"10.1111\/dth.15396","article-title":"Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation","volume":"35","author":"Akoglu","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1016\/j.jaad.2021.11.016","article-title":"Skin reactions to COVID-19 vaccines: An American Academy of Dermatology\/International League of Dermatological Societies registry update on reaction location and COVID vaccine type","volume":"86","author":"Freeman","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4103\/ds.ds_4_22","article-title":"AZ arm: Delayed cutaneous reaction to ChAdOx1 nCoV-19 (AZD1222) vaccine","volume":"40","author":"Hung","year":"2022","journal-title":"Dermatol. Sin."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/ds.ds_11_22","article-title":"Erythrodermic psoriasis following ChAdOx1 nCOV-19 vaccination: A case report","volume":"40","author":"Lin","year":"2022","journal-title":"Dermatol. Sin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e15153","DOI":"10.1111\/dth.15153","article-title":"Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: An observational study","volume":"34","author":"Grieco","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4103\/ds.DS-D-22-00121","article-title":"Dyshidrotic bullous pemphigoid developing after Moderna mRNA-1273 vaccination","volume":"41","author":"Hsieh","year":"2023","journal-title":"Dermatol. Sin."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.25270\/wmp.2022.11.2225","article-title":"Bullous Pemphigoid After Vaccination With the Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine: Two Cases in China","volume":"68","author":"Guo","year":"2022","journal-title":"Wound. Manag. Prev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/ijd.16086","article-title":"Can COVID-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center","volume":"61","author":"Afacan","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1111\/jdv.17955","article-title":"Incident bullous pemphigoid in a psoriatic patient following mRNA-1273 SARS-CoV-2 vaccination","volume":"36","author":"Hung","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fmed.2018.00296","article-title":"Diagnosis of Autoimmune Blistering Diseases","volume":"5","author":"Witte","year":"2018","journal-title":"Front. Med."},{"key":"ref_17","first-page":"405","article-title":"Autoimmune bullous dermatoses","volume":"21","author":"Holtsche","year":"2023","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1111\/jdv.17472","article-title":"The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: Is the second dose therefore contraindicated?","volume":"35","author":"Damiani","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/ced.14835","article-title":"Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: Report of four cases and review of the literature","volume":"47","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4103\/1027-8117.362992","article-title":"Ten essential steps for performing a systematic review: A quick tutorial","volume":"40","author":"Kuo","year":"2022","journal-title":"Dermatol. Sin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/ds.DS-D-22-00154","article-title":"Using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) to rate the certainty of evidence of study outcomes from systematic reviews: A quick tutorial","volume":"41","author":"Shao","year":"2023","journal-title":"Dermatol. Sin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid. Based Med."},{"key":"ref_24","unstructured":"National Institutes of Health (2023, January 16). Study Quality Assessment Tools, Available online: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"101108","DOI":"10.1016\/j.visj.2021.101108","article-title":"Moderna COVID-19 vaccine induced skin rash","volume":"25","author":"Khalid","year":"2021","journal-title":"Vis. J. Emerg. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e606","DOI":"10.1111\/1346-8138.16170","article-title":"Case of bullous pemphigoid following coronavirus disease 2019 vaccination","volume":"48","author":"Nakamura","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_27","first-page":"e333","article-title":"Bullous pemphigoid and COVID-19 vaccine","volume":"157","year":"2021","journal-title":"Med. Clin."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jaci.2021.06.026","article-title":"Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination","volume":"148","author":"Tomayko","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"103420","DOI":"10.1016\/j.amsu.2022.103420","article-title":"Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) COVID-19 vaccine: A case report","volume":"75","author":"Alshammari","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e876","DOI":"10.1111\/jdv.18386","article-title":"Cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: A real-life multicentre experience","volume":"36","author":"Avallone","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jdcr.2022.03.011","article-title":"A case report of anti-P200 pemphigoid following COVID-19 vaccination","volume":"23","author":"Jouen","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e15555","DOI":"10.1111\/dth.15555","article-title":"New-onset bullous pemphigoid and flare of pre-existing bullous pemphigoid after the third dose of the COVID-19 vaccine","volume":"35","author":"Bardazzi","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/bjd.21240","article-title":"Evaluating risk of bullous pemphigoid after mRNA COVID-19 vaccination","volume":"187","author":"Birabaharan","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e15241","DOI":"10.1111\/dth.15241","article-title":"New-onset bullous pemphigoid after inactivated COVID-19 vaccine: Synergistic effect of the COVID-19 vaccine and vildagliptin","volume":"35","author":"Bostan","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5070\/D328458525","article-title":"A new eruption of bullous pemphigoid following mRNA COVID-19 vaccination","volume":"28","author":"Daines","year":"2022","journal-title":"Dermatol. Online J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.21692","article-title":"Sweet-like syndrome and multiple COVID arm syndrome following COVID-19 vaccines: \u2018specific\u2019 patterns in a series of 192 patients","volume":"187","author":"Darrigade","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_37","first-page":"e15208","article-title":"Bullous pemphigoid triggered by COVID-19 vaccine: Rapid resolution with corticosteroid therapy","volume":"35","author":"Anedda","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_38","first-page":"e24126","article-title":"Bullous Pemphigoid Following the Moderna mRNA-1273 Vaccine","volume":"14","author":"Desai","year":"2022","journal-title":"Cureus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jfma.2022.02.017","article-title":"A case of acquired hemophilia A and bullous pemphigoid following SARS-CoV-2 mRNA vaccination","volume":"121","author":"Fu","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bjd.20890","article-title":"Bullous pemphigoid after SARS-CoV-2 vaccination: Spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies","volume":"186","author":"Gambichler","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_41","first-page":"e23127","article-title":"Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Series of Five Cases","volume":"14","author":"Hali","year":"2022","journal-title":"Cureus"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/cup.14104","article-title":"Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination","volume":"49","author":"Larson","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"841506","DOI":"10.3389\/fmed.2022.841506","article-title":"Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study","volume":"9","author":"Maronese","year":"2022","journal-title":"Front. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e15496","DOI":"10.1111\/dth.15496","article-title":"Reply to \u201cNew-onset bullous pemphigoid after inactivated COVID-19 vaccine: Synergistic effect of the COVID-19 vaccine and vildagliptin\u201d","volume":"35","author":"Maronese","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/1346-8138.16687","article-title":"SARS-CoV-2 vaccine-triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitors-associated bullous pemphigoid","volume":"50","author":"Nakahara","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_46","first-page":"e29786","article-title":"A patient develops bullous rash after receiving the second dose of COVID-19 vaccine","volume":"14","author":"Nida","year":"2022","journal-title":"Cureus"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1111\/jdv.17891","article-title":"Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: A report and brief literature review","volume":"36","author":"Pauluzzi","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"834316","DOI":"10.3389\/fimmu.2022.834316","article-title":"Absolving COVID-19 Vaccination of Autoimmune Bullous Disease Onset","volume":"13","author":"Russo","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_49","first-page":"e30541","article-title":"The Successful Treatment of COVID-19-Induced Bullous Pemphigoid With Dupilumab","volume":"14","author":"Savoldy","year":"2022","journal-title":"Cureus"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1111\/jdv.17722","article-title":"Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA-1273 vaccine in an 84-year-old female with polymorbidity and polypharmacy","volume":"36","author":"Schmidt","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e15651","DOI":"10.1111\/dth.15651","article-title":"Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases","volume":"35","author":"Shakoei","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_52","first-page":"e26383","article-title":"Dyshidrosiform Bullous Pemphigoid Triggered by COVID-19 Vaccination","volume":"14","author":"Shanshal","year":"2022","journal-title":"Cureus"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2050313X221131868","DOI":"10.1177\/2050313X221131868","article-title":"Association between COVID-19 vaccination and bullous pemphigoid\u2014A case series and literature review","volume":"10","author":"Wan","year":"2022","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1111\/jdv.17676","article-title":"A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine","volume":"36","author":"Young","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e15595","DOI":"10.1111\/dth.15595","article-title":"Bullous pemphigoid after inactivated COVID-19 vaccination: Case report","volume":"35","author":"Zhang","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1111\/jdv.18673","article-title":"Severe bullous pemphigoid following COVID-19 vaccination resistant to rituximab and successfully treated with dupilumab","volume":"37","author":"Baffa","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1117176","DOI":"10.3389\/fmed.2022.1117176","article-title":"Autoimmune blistering skin diseases triggered by COVID-19 vaccinations: An Australian case series","volume":"9","author":"Cowan","year":"2023","journal-title":"Front. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"590","DOI":"10.4103\/ijd.ijd_519_23","article-title":"COVID-19 Vaccine-Triggered Bullous Pemphigoid: Two New Cases from Saudi Arabia","volume":"68","author":"Dawoud","year":"2023","journal-title":"Indian J. Dermatol."},{"key":"ref_59","first-page":"730","article-title":"Bullous pemphigoid associated with COVID-19 vaccine in child: A case report","volume":"33","author":"Mulianto","year":"2023","journal-title":"J. Pak. Assoc. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e578","DOI":"10.1111\/jdv.18893","article-title":"Reply to: \u2018Severe bullous pemphigoid following COVID-19 vaccination resistant to rituximab and successfully treated with dupilumab\u2019 by Baffa et al","volume":"37","author":"Sun","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/jocd.15570","article-title":"Skin manifestations following anti-COVID-19 vaccination: A multicentricstudy from Turkey","volume":"22","author":"Tokmak","year":"2023","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4274\/jtad.galenos.2022.70883","article-title":"COVID-19 Vaccine Induced Bullous Pemphigoid: Case Report and Review of the Literature","volume":"17","year":"2023","journal-title":"J. Turk. Acad. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/jocd.16042","article-title":"Clinicopathological characteristics of cutaneous complications following COVID-19 vaccination: A case series","volume":"23","author":"Diab","year":"2024","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/1346-8138.16940","article-title":"Bullous pemphigoid associated with prodromal-phase by repeated COVID-19 vaccinations","volume":"51","author":"Yamamoto","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"E2","DOI":"10.12788\/cutis.0772","article-title":"New-Onset Pemphigoid Gestationis Following COVID-19 Vaccination","volume":"111","author":"Mustin","year":"2023","journal-title":"Cutis"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s12105-023-01539-9","article-title":"Mucous Membrane Pemphigoid Following the Administration of COVID-19 Vaccine","volume":"17","author":"Rungraungrayabkul","year":"2023","journal-title":"Head Neck Pathol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/odi.14468","article-title":"Oral mucous membrane pemphigoid after SARS-CoV-2 vaccination","volume":"30","author":"Calabria","year":"2024","journal-title":"Oral Diseases"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/ced.15007","article-title":"Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine","volume":"47","author":"Hali","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jdcr.2022.04.021","article-title":"Toxic epidermal necrolysis-like linear IgA bullous dermatosis after third Moderna COVID-19 vaccine in the setting of oral terbinafine","volume":"24","author":"Han","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/cup.14305","article-title":"Eosinophil-rich linear IgA bullous dermatosis induced by mRNA COVID-19 booster vaccine","volume":"50","author":"Nahm","year":"2023","journal-title":"J. Cutan. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e649","DOI":"10.1111\/jdv.17480","article-title":"Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2","volume":"35","author":"Solimani","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e15769","DOI":"10.1111\/dth.15769","article-title":"Pemphigus vulgaris following second dose of mRNA-(Pfizer-BioNTech) COVID-19 vaccine","volume":"35","author":"Agharbi","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_73","first-page":"2324212","article-title":"Coexistence of Pemphigus Vulgaris and Lichen Planus following COVID-19 Vaccination","volume":"2022","author":"Aryanian","year":"2022","journal-title":"Case Rep. Dermatol. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"153834","DOI":"10.1016\/j.prp.2022.153834","article-title":"Autoimmune mucocutaneous blistering diseases after SARS-CoV-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review","volume":"232","author":"Calabria","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/1346-8138.16554","article-title":"Five cases of new-onset pemphigus following vaccinations against coronavirus disease 2019","volume":"50","author":"Corra","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.1111\/jdv.17951","article-title":"A study of COVID-19 vaccine (Covishield) induced dermatological adverse effects from India","volume":"36","author":"Das","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e15216","DOI":"10.1111\/dth.15216","article-title":"COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus","volume":"35","author":"Hatami","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1111\/jdv.17868","article-title":"Development of pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient","volume":"36","author":"Knechtl","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1111\/odi.14089","article-title":"Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-CoV-2 vaccine","volume":"28","author":"Koutlas","year":"2022","journal-title":"Oral Dis."},{"key":"ref_80","first-page":"e74","article-title":"Pemphigus vulgaris with advanced hypopharyngeal and gastric cancer following SARS-CoV-2 vaccination","volume":"50","author":"Norimatsu","year":"2022","journal-title":"J Dermatol"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e15448","DOI":"10.1111\/dth.15448","article-title":"De novo severe pemphigus vulgaris following SARS-CoV-2 vaccination with BBIBP-CorV","volume":"35","author":"Saffarian","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1111\/jocd.14945","article-title":"Development of severe pemphigus vulgaris following ChAdOx1 nCoV-19 vaccination and review of literature","volume":"21","author":"Singh","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1111\/odi.14034","article-title":"Oral pemphigus after COVID-19 vaccination","volume":"28","author":"Thongprasom","year":"2022","journal-title":"Oral. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"E544","DOI":"10.1097\/MJT.0000000000001620","article-title":"Rituximab for COVID-19 Vaccine-Associated Pemphigus Vulgaris","volume":"30","author":"Hui","year":"2023","journal-title":"Am. J. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s13256-023-04055-0","article-title":"Pemphigus vulgaris after the second dose of COVID-19 vaccination: A case report","volume":"17","author":"Khalayli","year":"2023","journal-title":"J. Med. Case Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e15775","DOI":"10.1111\/dth.15775","article-title":"Pemphigus foliaceus triggered after inactivated SARS-CoV-2 vaccine: Coincidence or causal link?","volume":"35","author":"Alami","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jdcr.2022.07.002","article-title":"New-onset pemphigus vegetans and pemphigus foliaceus after SARS-CoV-2 vaccination: A report of 2 cases","volume":"27","author":"Gui","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/ajd.13755","article-title":"An unusual presentation of pemphigus foliaceus following COVID-19 vaccination","volume":"63","author":"Lua","year":"2022","journal-title":"Australas. J. Dermatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e15816","DOI":"10.1111\/dth.15816","article-title":"New onset of pemphigus foliaceus following BBIBP COVID-19 vaccine","volume":"35","author":"Pourani","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1684\/ejd.2022.4294","article-title":"Pemphigus foliaceous after mRNA COVID-19 vaccine","volume":"32","author":"Reis","year":"2022","journal-title":"Eur. J. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e15827","DOI":"10.1111\/dth.15827","article-title":"Two cases with new onset of pemphigus foliaceus after SARS-CoV-2 vaccination","volume":"35","author":"Rouatbi","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e15381","DOI":"10.1111\/dth.15381","article-title":"New onset of pemphigus foliaceus following BNT162b2 vaccine","volume":"35","author":"Yildirici","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_93","first-page":"e1","article-title":"New onset pemphigus foliaceus following AstraZeneca COVID-19 vaccination","volume":"37","author":"Ayyalaraju","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_94","first-page":"1218388","article-title":"Pemphigus Foliaceus after COVID-19 Vaccination: A Report of Two Cases","volume":"2023","author":"Pham","year":"2023","journal-title":"Case Rep. Dermatol. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2147\/CCID.S410690","article-title":"Cutaneous Adverse Events After COVID-19 Vaccination","volume":"16","author":"Weschawalit","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e976","DOI":"10.1111\/jdv.18398","article-title":"Reply to \u2018development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2\u2019 by Solimani F et al","volume":"36","author":"Falcinelli","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2050313X231181022","DOI":"10.1177\/2050313X231181022","article-title":"IgA pemphigus following COVID-19 vaccination: A case report","volume":"11","author":"Lansang","year":"2023","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"957169","DOI":"10.3389\/fmed.2022.957169","article-title":"Exacerbation of Autoimmune Bullous Diseases After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: Is There Any Association?","volume":"9","author":"Kianfar","year":"2022","journal-title":"Front. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e12785","DOI":"10.1002\/rth2.12785","article-title":"Acquired hemophilia following COVID-19 vaccination: Case report and review of literature","volume":"6","author":"Happaerts","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e855","DOI":"10.1111\/jdv.17581","article-title":"Three cases of vesiculobullous non-IgE-mediated cutaneous reactions to tozinameran (Pfizer-BioNTech COVID-19 vaccine)","volume":"35","author":"Juay","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/jdv.18503","article-title":"Bullous pemphigoid and COVID-19 vaccination: Management and treatment reply to \u2018Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: A report and brief literature review\u2019 by Pauluzzi et al","volume":"37","author":"Martora","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1111\/jdv.17883","article-title":"Cutaneous manifestations following COVID-19 vaccination: A multicentric descriptive cohort","volume":"36","author":"Massip","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s13256-023-04146-y","article-title":"Autoimmune bullous disorder flares following severe acute respiratory syndrome coronavirus 2 vaccination: A case series","volume":"17","author":"Rasner","year":"2023","journal-title":"J. Med. Case Rep."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1093827","DOI":"10.3389\/fmed.2023.1093827","article-title":"Case report: A case of epidermolysis bullosa acquisita with IgG and IgM anti-basement membrane zone antibodies relapsed after COVID-19 mRNA vaccination","volume":"10","author":"Minakawa","year":"2023","journal-title":"Front. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1111\/jdv.17959","article-title":"Reply to \u2018The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: Is the second dose therefore contraindicated?\u2019 by Damiani G et al","volume":"36","author":"Avallone","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e750","DOI":"10.1111\/jdv.18302","article-title":"Reply to \u2018Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2\u2019 by Solimani et al","volume":"36","author":"Martora","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jdcr.2022.01.027","article-title":"Severe flare of pemphigus vulgaris after first dose of COVID-19 vaccine","volume":"22","author":"Ong","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e15354","DOI":"10.1111\/dth.15354","article-title":"Pemphigus vulgaris relapse during the coronavirus disease pandemic","volume":"35","author":"Saleh","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/1756-185X.14581","article-title":"Pemphigus aggravation following Pfizer-BioNTech vaccination: A case report and review of literature","volume":"26","author":"Chen","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e1369","DOI":"10.1111\/jdv.19414","article-title":"A severe relapse of pemphigus vulgaris after SARS-CoV-2 vaccination","volume":"37","author":"Ligrone","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_111","first-page":"e15820","article-title":"Adverse cutaneous reactions reported post COVID-19 vaccination in Al Buraimi governorate, Sultanate of Oman","volume":"35","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e15417","DOI":"10.1111\/dth.15417","article-title":"COVID-19 severity and SARS-CoV-2 vaccine safety in pemphigus patients","volume":"35","author":"Ozgen","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_113","first-page":"e9","article-title":"Safety of the COVID-19 vaccine booster in patients with immunobullous diseases: A cross-sectional study of the International Pemphigus and Pemphigoid Foundation","volume":"37","author":"Kasperkiewicz","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_114","first-page":"1305","article-title":"Association between bullous pemphigoid and psychiatric disorders: A systematic review and meta-analysis","volume":"20","author":"Huang","year":"2022","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/archdermatol.2010.322","article-title":"The association of bullous pemphigoid with cerebrovascular disease and dementia: A case-control study","volume":"146","author":"Taghipour","year":"2010","journal-title":"Arch. Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","article-title":"Association between medication use and bullous pemphigoid: A systematic review and meta-analysis","volume":"156","author":"Liu","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e00373","DOI":"10.1002\/prp2.373","article-title":"Improving the assessment of adverse drug reactions using the Naranjo Algorithm in daily practice: The Japan Adverse Drug Events Study","volume":"6","author":"Murayama","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/bjd.17591","article-title":"Clinical and immunological features of pemphigus relapse","volume":"180","author":"Ujiie","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s13167-017-0101-y","article-title":"Vaccination and autoimmune diseases: Is prevention of adverse health effects on the horizon?","volume":"8","author":"Vadala","year":"2017","journal-title":"EPMA J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2021.04.061","article-title":"Association between vaccination and autoimmune bullous diseases: A systematic review","volume":"86","author":"Kasperkiewicz","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"104266","DOI":"10.1016\/j.amsu.2022.104266","article-title":"Bullous pemphigoid following COVID-19 vaccine: An autoimmune disorder","volume":"80","author":"Aashish","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"931872","DOI":"10.3389\/fmed.2022.931872","article-title":"May bullous pemphigoid be worsened by COVID-19 vaccine?","volume":"9","author":"Cozzani","year":"2022","journal-title":"Front. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI28547","article-title":"T cell control in autoimmune bullous skin disorders","volume":"116","author":"Hertl","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Sernicola, A., Mazzetto, R., Tartaglia, J., Ciolfi, C., Miceli, P., and Alaibac, M. (2023). Role of Human Leukocyte Antigen Class II in Antibody-Mediated Skin Disorders. Medicina, 59.","DOI":"10.3390\/medicina59111950"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"807711","DOI":"10.3389\/fmed.2021.807711","article-title":"Case Report: Circulating Anti-SARS-CoV-2 Antibodies Do Not Cross-React With Pemphigus or Pemphigoid Autoantigens","volume":"8","author":"Kasperkiewicz","year":"2021","journal-title":"Front. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e665","DOI":"10.1111\/jdv.18202","article-title":"Association between COVID-19 vaccination and autoimmune bullous diseases: A random coincidence or rare event","volume":"36","author":"Kasperkiewicz","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1111\/jdv.18030","article-title":"Association between vaccination and immunobullous disorders: A brief, updated systematic review with focus on COVID-19","volume":"36","author":"Kasperkiewicz","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Moro, F., Fania, L., Sinagra, J.L.M., Salemme, A., and Di Zenzo, G. (2020). Bullous pemphigoid: Trigger and predisposing factors. Biomolecules, 10.","DOI":"10.3390\/biom10101432"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4103\/ds.DS-D-23-00159","article-title":"Levels of evidence and study designs: A brief introduction to dermato-epidemiologic research methodology","volume":"41","author":"Chen","year":"2023","journal-title":"Dermatol. Sin."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/5\/465\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:34:23Z","timestamp":1760106863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/5\/465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":129,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["vaccines12050465"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12050465","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]}}}